Report Interpretation

Overview

The report focuses on Centre Testing's 2Q26 results, its five major business segments, overseas M&A integration, and long-term expansion potential. HSBC believes that the company's profit recovery since 3Q25 has gradually evolved into structural growth. Medical testing, export-related consumer testing, and overseas network expansion are current highlights, while longer-term drivers also include positioning in emerging industries, M&A, and artificial intelligence applications.

Core views

2Q26 results were broadly in line with market and HSBC expectations, but the report emphasizes that achieving this growth was not easy amid generally weak industry conditions. Quarterly revenue was RMB1.935bn, up 15.6% YoY, while net profit was RMB385m, up 16.4% YoY. Gross margin was 52.0%, down only 0.1 percentage points YoY. Expense ratios other than administrative expenses declined YoY, allowing net profit to grow faster than revenue. HSBC estimates that, excluding the consolidation impact of newly acquired subsidiaries, organic growth contributed approximately 10 percentage points to 2Q26 revenue growth, mainly driven by a recovery in the medical business and stronger demand for export-related consumer testing. The report contrasts the recent improvement with the operational challenges from 2021 through 1H25. The company resumed net profit growth in 3Q25 and maintained solid performance in 2H25 and 1H26 despite weak industry conditions, indicating that its expansion strategy is working rather than merely benefiting from a cyclical industry rebound. HSBC believes overseas expansion, M&A, early positioning in emerging industries, and artificial intelligence applications constitute long-term growth drivers. Most revenue is recurring and relatively less cyclical, so sustainable growth may continue beyond 2028. Compared with leading global testing institutions, the company's business is already relatively diversified, but its scale remains small and globalization is still at an early stage. The report believes that deeper cooperation between Chinese and overseas markets could enable the company to strengthen its competitive advantages through its global laboratory network and international credibility. Overseas operations were an important highlight in 1H26. Overseas revenue increased 62.9% YoY, with its share of total revenue rising from 7.47% in 2025 to 12.15%. Growth partly came from the consolidation of acquired subsidiaries, but HSBC believes the company is promoting synergies between newly acquired entities and its existing operations, which could improve overseas business margins in the future. Food and environment testing revenue increased 12.3% YoY, while gross margin was 49.86%, down 1.30 percentage points YoY. Despite slower industry growth, the company achieved faster growth through acquisitions and expansion of its service network. The integration of its South African food safety business expanded its service network across China, Southeast Asia, and Africa, while France's MIDAC laboratory strengthened its international compliance service capabilities for personal care products and food. Industrial testing revenue increased 19.0% YoY, while gross margin was 41.85%, down 1.53 percentage points YoY. Carbon verification, materials testing, and metrology grew rapidly, but engineering construction and marine testing remained in a downcycle. The South African subsidiary completed preliminary integration and contributed incremental growth, while NAIAS's global marine fuel testing business is also advancing synergies among domestic and overseas laboratories and customer resources. Consumer testing revenue increased 12.7% YoY, while gross margin was 46.83%, up 5.36 percentage points YoY. Domestic demand remained weak, but export-related testing demand was strong, and economies of scale supported margin improvement. Automotive electronics electromagnetic compatibility testing grew significantly. The relocation of VESP Tech's new laboratory resolved capacity bottlenecks, while growth in high-margin operations further improved profitability. Trade assurance revenue increased 12.8% YoY, while gross margin was 71.68%, down 1.64 percentage points YoY. Economies of scale in electronic materials chemistry and reliability testing became increasingly evident, while the integration of Microtech's PCB testing business and Openview's international audit business continued to generate positive results. Medical testing was the fastest-growing segment, with revenue increasing 57.4% YoY and gross margin reaching 28.48%, up 9.08 percentage points YoY. The report attributes this to a combination of improving industry conditions and the company's own investments, including upstream positioning in laboratory animal resources, continued capacity ramp-up in medical devices, and comprehensive entry into the biosafety field through acquisitions. Based on the results and segment trends, HSBC raised its 2026-28 earnings forecasts by 0.9%, 1.4%, and 2.0%, respectively. In terms of the adjustment mix, revenue forecasts for industrial and consumer testing were slightly reduced, while the medical testing revenue forecast was raised significantly, alongside adjustments to gross margin and operating expense assumptions. Revenue forecasts for 2026-28 are RMB7.649bn, RMB8.759bn, and RMB10.086bn, respectively; net profit forecasts are RMB1.212bn, RMB1.417bn, and RMB1.624bn; and EPS forecasts are RMB0.72, RMB0.84, and RMB0.96, respectively. The report forecasts a 16.9% earnings CAGR for 2025-28, significantly above the 8.0% recorded during 2021-25. On valuation, HSBC continues to use a DCF model and raises its target price from RMB20.60 to RMB20.98 due to changes in earnings forecasts and valuation assumptions. This implies approximately 37.8% upside from the RMB15.22 share price as of August 18, 2026, supporting its reiterated Buy rating. The DCF uses an 8.5% cost of equity, calculated from a 4.25% risk-free rate, a 4.75% market risk premium, and a beta of 0.89. The pre-tax cost of debt is 5.0% and the after-tax cost is 4.3%, while the long-term debt-to-capital ratio is assumed to be 0%, resulting in a WACC of 8.5%. The model assumes a 10.6% CAGR in operating cash flow before changes in working capital from 2025 to 2038. Capital expenditure is projected at RMB770m in 2026, rising gradually from RMB852m in 2027 to RMB2.004bn in 2038. The model assumes steady-state growth after 2038 with a 2% perpetual growth rate. Relative valuation also supports the report's positive view. The stock currently trades at 18.1x forecast 2027 P/E, below its historical average of 45x since 2015. HSBC believes that the company's market leadership, favorable revenue mix, diversified businesses and customers, and potential global network advantages justify a valuation premium over domestic and international peers. The report also notes that reputation and credibility, margin pressure from intensifying competition, slower-than-expected ramp-up of new laboratories and businesses, and uncertainty relating to M&A execution, target valuations, and regulation are the main constraints on achieving long-term growth and the valuation target.

Analysis framework

The report first assesses whether 2Q26 revenue, profit, and expense performance met expectations, then separates consolidation-driven growth from organic growth and analyzes the revenue, gross margin, and drivers of each of the five major business segments. It subsequently compares recent performance with the weak period from 2021 through 1H25 and explains the structural growth thesis through the overseas network, M&A synergies, positioning in emerging industries, and artificial intelligence applications. On this basis, it adjusts 2026-28 segment revenue, margin, and earnings forecasts, determines the target price using DCF, compares the valuation with historical and peer P/E multiples, and lists catalysts and downside risks.

Methodology notes

• Valuation methodologyDCF discounted cash flow

  Discounted cash flow valuation

  The report forecasts the company's free cash flow through 2038 and discounts it using an 8.5% WACC. It applies a 2% perpetual growth rate after 2038 to calculate terminal value, resulting in a target value of RMB20.98 per share.

• Quantitative/Factor/Portfolio TheoryCAPM capital asset pricing

  Cost of equity calculation

  The report uses a 4.25% risk-free rate, a 4.75% market risk premium, and a beta of 0.89 to calculate an 8.5% cost of equity, which serves as the core input for the DCF discount rate.

• Valuation methodologyPE/PEG valuation

  Forward P/E, historical average, and peer comparison

  The report compares the 18.1x forecast 2027 P/E with the historical average P/E of 45x since 2015 and incorporates domestic and international peer valuations to assess whether the current pricing reflects the company's growth and competitive advantages.

• Competition and strategy frameworkEconomies of scale / learning curve

  Laboratory and business economies of scale

  The report uses revenue growth and margin changes in businesses such as consumer testing, electronic materials chemistry, and reliability testing to assess how higher laboratory capacity utilization and expanded business scale enhance profitability.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Centre Testing Intl Group (300012.SS)

  The report's primary research and rating subject; overseas expansion, M&A integration, recovery in the medical business, and export testing demand are viewed as sources of long-term growth.

  Strengths

  Diversified business and customer mix, with most revenue being recurring; rapid growth in medical and export-related businesses, alongside an expanding laboratory network, accumulated data, and potential artificial intelligence applications.

  Weaknesses

  Its global scale remains significantly smaller than that of leading international testing institutions. Demand remains weak in certain industrial testing subsectors and domestic consumer testing, while gross margins declined YoY in several segments.

  Comparison

  The report believes that the company's current 18.1x forecast 2027 P/E is below its historical average of 45x since 2015 and that its market leadership and revenue mix justify a premium over domestic and international peers.

  Risks

  Damage to reputation or credibility, margin compression from competition, slower-than-expected ramp-up of new laboratories and businesses, and uncertainty relating to M&A execution, target valuations, and regulation.

Key data

• 2Q26 revenueRMB1.935bnUp 15.6% YoY, broadly in line with market and HSBC expectations.
• 2Q26 net profitRMB385mUp 16.4% YoY, growing faster than revenue.
• 2Q26 gross margin52.0%Down only 0.1 percentage points YoY.
• Estimated organic growth contributionApproximately 10 percentage pointsRefers to the estimated contribution to 2Q26 YoY revenue growth after excluding the consolidation of newly acquired subsidiaries.
• 1H26 overseas revenue growth62.9%The overseas revenue share rose to 12.15%, versus 7.47% in 2025.
• Medical testingRevenue +57.4% YoY; gross margin 28.48%Gross margin increased 9.08 percentage points YoY, making it the fastest-growing of the five major segments.
• Consumer testingRevenue +12.7% YoY; gross margin 46.83%Gross margin increased 5.36 percentage points YoY, supported by export demand and economies of scale.
• Industrial testingRevenue +19.0% YoY; gross margin 41.85%Gross margin declined 1.53 percentage points YoY.
• Food and environment testingRevenue +12.3% YoY; gross margin 49.86%Gross margin declined 1.30 percentage points YoY.
• Trade assuranceRevenue +12.8% YoY; gross margin 71.68%Gross margin declined 1.64 percentage points YoY.
• 2026-28 earnings forecast adjustments+0.9%, +1.4%, +2.0%The medical testing forecast was raised substantially, while revenue forecasts for industrial and consumer testing were reduced slightly.
• 2026-28 EPS forecastsRMB0.72, RMB0.84, RMB0.96Previous forecasts were RMB0.71, RMB0.83, and RMB0.95, respectively.
• 2025-28 earnings CAGR16.9%Above the 8.0% recorded during 2021-25.
• Forecast 2027 P/E18.1xBelow the historical average P/E of 45x since 2015.
• DCF target priceRMB20.98Versus RMB20.60 previously, implying approximately 37.8% upside from the current price.
• Core DCF assumptionsWACC 8.5%; perpetual growth rate 2%Cost of equity of 8.5%, long-term debt-to-capital ratio of 0%, and steady-state growth after 2038.

Impact & implications

The report believes the significance of earnings growth has shifted from a short-term recovery to long-term structural expansion. A higher overseas revenue contribution, synergies from acquired businesses, rapid medical testing growth, and export-related testing demand could expand the company's serviceable market and improve its business mix. Continued development of a global laboratory network and credibility could strengthen competitive barriers. Higher earnings forecasts and adjustments to DCF parameters support a modest target price increase, while a forward P/E significantly below the historical average provides relative valuation support for the reiterated Buy rating.

Risks

• Reputational or credibility incidents could result in the loss of customers and operating licenses and hinder business growth and financial performance.
• The entry of more market participants could intensify competition and compress margins.
• There is uncertainty surrounding the capacity ramp-up of newly built laboratories and new testing businesses, and performance could fall below expectations.
• M&A transactions may face uncertainty relating to execution, target valuations, and regulation.

What to watch

• Watch whether specific policies and regulatory details permitting the import of experimental materials for medical safety evaluations are announced.
• Watch whether the integration of acquired subsidiaries in the medical or semiconductor fields can be completed smoothly.
• Watch whether further policies for China's carbon verification and carbon trading markets are implemented during 2026.